The primary advantage of using nanoparticles in immunosuppressive therapies is their ability to improve drug bioavailability. Traditional immunosuppressive drugs often suffer from poor solubility and rapid degradation. Nanoparticles can encapsulate these drugs, protecting them from degradation and enhancing their stability. Additionally, the surface of nanoparticles can be modified with specific ligands or antibodies to enable targeted drug delivery, ensuring that the drugs exert their effects precisely where needed.
